B
300558
vs
S
Shanghai Composite
Over the past 12 months, Betta Pharmaceuticals Co Ltd has underperformed Shanghai Composite, delivering a return of -13% compared to the Shanghai Composite's +21% growth.
Stocks Performance
300558 vs Shanghai Composite
Performance Gap
300558 vs Shanghai Composite
Performance By Year
300558 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Betta Pharmaceuticals Co Ltd
Glance View
Betta Pharmaceuticals Co Ltd., established in 2003, is a dynamic player in China's rapidly evolving pharmaceutical landscape. The company made its mark with a particular focus on the research, development, production, and sale of innovative oncology drugs. Its flagship product, icotinib, a breakthrough therapy for non-small cell lung cancer, propelled Betta Pharmaceuticals into the spotlight, underpinning their pursuit of excellence in targeted cancer treatment. By capitalizing on expertise in small molecule drug discovery, Betta Pharmaceuticals transformed from a bold idea into a critical partner for healthcare providers, offering proprietary products that serve unmet medical needs across China and beyond. Driving its business model is a robust pipeline fueled by an ongoing commitment to research and innovation. Betta Pharmaceuticals thrives on its biodiverse R&D programs which are facilitated through collaborations with world-class research institutes and industry partners. The company's revenues predominantly flow from sales of its own branded oncology drugs, supplemented by royalty streams from licensing agreements. Their approach blends a careful balance of keen scientific inquiry with commercial acumen, as Betta continually reinvests in clinical trials and regulatory approvals to bring new drugs to market. Thus, the company's ability to blend innovation with practical application keeps it well-positioned amid the competitive and ever-evolving global pharmaceutical arena.
